Veru Inc. VERU
2.09 USD -0.03 (-1.42%)
At closeNov 13, 2026, 4:00 PM EST
2.09 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
2.08 Day range 2.15
2.04 52-week range 7.33
- YTD
- -2.34%
- 1 year
- -16.73%
News
benzinga.com Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026 Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief…
globenewswire.com Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026 MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic…
benzinga.com WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28 WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
globenewswire.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial --New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer…
globenewswire.com Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
seekingalpha.com Veru Inc. (VERU) Q3 2026 Earnings Call Transcript Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
benzinga.com Veru Q3 EPS $(0.30) Beats $(0.32) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share…
globenewswire.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
globenewswire.com Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss -- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of…
globenewswire.com Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
globenewswire.com Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
benzinga.com Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced…
globenewswire.com Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss -- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc.…
globenewswire.com Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
benzinga.com Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24 Oppenheimer analyst Leland Gershell maintains Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $25 to $24.
seekingalpha.com Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
benzinga.com Transcript: Veru Q2 2026 Earnings Conference Call 
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Veru Q2 EPS $(0.12) Beats $(0.28) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.28) by 57.14 percent. This is a 76 percent increase over losses of $(0.50) per share…
globenewswire.com Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress --Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
globenewswire.com Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
defenseworld.net Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.64 and traded as low as…
defenseworld.net Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell? Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.69 and traded as low as $2.39. Veru…
benzinga.com Veru Files Prospectus For Offering $200M Mixed Shelf https://www.sec.gov/Archives/edgar/data/863894/000119312526145576/d84893ds3.htm
defenseworld.net Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.81 and traded as low as…
benzinga.com Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older…
globenewswire.com Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older…
seekingalpha.com Veru Inc. (VERU) Q1 2026 Earnings Call Transcript Veru Inc. (VERU) Q1 2026 Earnings Call Transcript- benzinga.com Veru Q1 EPS $(0.26) Beats $(0.47) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.47) by 44.68 percent. This is a 57.38 percent increase over losses of $(0.61) per…
- benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com A Look at Veru's Upcoming Earnings Report 
defenseworld.net Flora Growth (NASDAQ:FLGC) and Veru (NASDAQ:VERU) Financial Review Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based…
globenewswire.com Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25 Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $25.
- benzinga.com Earnings Scheduled For December 17, 2025
benzinga.com A Look Ahead: Veru's Earnings Forecast 
benzinga.com Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings 
benzinga.com Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More Investors are prepping for this week's earnings reports which include homebuilders, several apparel companies and a big tech company.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For August 12, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Earnings Scheduled For February 13, 2025 - benzinga.com 12 Consumer Staples Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Consumer Staples Stocks Moving In Thursday's After-Market Session